BioNTech SE

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, VRTX has a market cap of 101.2B. Regarding current trading prices, BNTX is priced at $106.83, while VRTX trades at $390.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas VRTX's P/E ratio is 28.05. In terms of profitability, BNTX's ROE is -0.02%, compared to VRTX's ROE of +0.22%. Regarding short-term risk, BNTX is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check VRTX's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, REGN has a market cap of 61.4B. Regarding current trading prices, BNTX is priced at $106.83, while REGN trades at $575.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas REGN's P/E ratio is 14.86. In terms of profitability, BNTX's ROE is -0.02%, compared to REGN's ROE of +0.15%. Regarding short-term risk, BNTX is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check REGN's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, ALNY has a market cap of 59.6B. Regarding current trading prices, BNTX is priced at $106.83, while ALNY trades at $446.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas ALNY's P/E ratio is -184.02. In terms of profitability, BNTX's ROE is -0.02%, compared to ALNY's ROE of -2.74%. Regarding short-term risk, BNTX is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check ALNY's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, BNTX is priced at $106.83, while SGEN trades at $228.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas SGEN's P/E ratio is -57.19. In terms of profitability, BNTX's ROE is -0.02%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, BNTX is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check SGEN's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, ARGX has a market cap of 40.4B. Regarding current trading prices, BNTX is priced at $106.83, while ARGX trades at $682.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas ARGX's P/E ratio is 33.59. In terms of profitability, BNTX's ROE is -0.02%, compared to ARGX's ROE of +0.26%. Regarding short-term risk, BNTX is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check ARGX's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, BNTX is priced at $106.83, while BGNE trades at $184.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas BGNE's P/E ratio is -22.55. In terms of profitability, BNTX's ROE is -0.02%, compared to BGNE's ROE of -0.05%. Regarding short-term risk, BNTX is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check BGNE's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, SMMT has a market cap of 19.5B. Regarding current trading prices, BNTX is priced at $106.83, while SMMT trades at $26.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas SMMT's P/E ratio is -25.94. In terms of profitability, BNTX's ROE is -0.02%, compared to SMMT's ROE of -2.09%. Regarding short-term risk, BNTX is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check SMMT's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, BNTX is priced at $106.83, while DNA-WT trades at $0.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, BNTX's ROE is -0.02%, compared to DNA-WT's ROE of -0.45%. Regarding short-term risk, BNTX is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for BNTX.Check DNA-WT's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, INCY has a market cap of 16.6B. Regarding current trading prices, BNTX is priced at $106.83, while INCY trades at $85.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas INCY's P/E ratio is 20.10. In terms of profitability, BNTX's ROE is -0.02%, compared to INCY's ROE of +0.24%. Regarding short-term risk, BNTX is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check INCY's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, RPRX has a market cap of 15.7B. Regarding current trading prices, BNTX is priced at $106.83, while RPRX trades at $35.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas RPRX's P/E ratio is 15.86. In terms of profitability, BNTX's ROE is -0.02%, compared to RPRX's ROE of +0.15%. Regarding short-term risk, BNTX is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check RPRX's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, GMAB has a market cap of 15.6B. Regarding current trading prices, BNTX is priced at $106.83, while GMAB trades at $24.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas GMAB's P/E ratio is 12.77. In terms of profitability, BNTX's ROE is -0.02%, compared to GMAB's ROE of +0.28%. Regarding short-term risk, BNTX is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check GMAB's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, UTHR has a market cap of 14.1B. Regarding current trading prices, BNTX is priced at $106.83, while UTHR trades at $306.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas UTHR's P/E ratio is 12.18. In terms of profitability, BNTX's ROE is -0.02%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, BNTX is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check UTHR's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, BNTX is priced at $106.83, while KRTX trades at $329.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas KRTX's P/E ratio is -28.09. In terms of profitability, BNTX's ROE is -0.02%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, BNTX is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check KRTX's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, ASND has a market cap of 11.8B. Regarding current trading prices, BNTX is priced at $106.83, while ASND trades at $195.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas ASND's P/E ratio is -36.83. In terms of profitability, BNTX's ROE is -0.02%, compared to ASND's ROE of +1.52%. Regarding short-term risk, BNTX is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check ASND's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, BMRN has a market cap of 11.2B. Regarding current trading prices, BNTX is priced at $106.83, while BMRN trades at $57.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas BMRN's P/E ratio is 17.28. In terms of profitability, BNTX's ROE is -0.02%, compared to BMRN's ROE of +0.11%. Regarding short-term risk, BNTX is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check BMRN's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, MRNA has a market cap of 10.6B. Regarding current trading prices, BNTX is priced at $106.83, while MRNA trades at $26.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas MRNA's P/E ratio is -3.61. In terms of profitability, BNTX's ROE is -0.02%, compared to MRNA's ROE of -0.27%. Regarding short-term risk, BNTX is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for BNTX.Check MRNA's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, EXEL has a market cap of 10.4B. Regarding current trading prices, BNTX is priced at $106.83, while EXEL trades at $38.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas EXEL's P/E ratio is 18.57. In terms of profitability, BNTX's ROE is -0.02%, compared to EXEL's ROE of +0.28%. Regarding short-term risk, BNTX is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check EXEL's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, BNTX is priced at $106.83, while RXDX trades at $199.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas RXDX's P/E ratio is -56.47. In terms of profitability, BNTX's ROE is -0.02%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, BNTX is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check RXDX's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, BBIO has a market cap of 9.4B. Regarding current trading prices, BNTX is priced at $106.83, while BBIO trades at $47.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas BBIO's P/E ratio is -11.88. In terms of profitability, BNTX's ROE is -0.02%, compared to BBIO's ROE of +0.51%. Regarding short-term risk, BNTX is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check BBIO's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, MDGL has a market cap of 9.2B. Regarding current trading prices, BNTX is priced at $106.83, while MDGL trades at $414.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas MDGL's P/E ratio is -32.78. In terms of profitability, BNTX's ROE is -0.02%, compared to MDGL's ROE of -0.38%. Regarding short-term risk, BNTX is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check MDGL's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, VRNA has a market cap of 9B. Regarding current trading prices, BNTX is priced at $106.83, while VRNA trades at $105.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas VRNA's P/E ratio is -101.50. In terms of profitability, BNTX's ROE is -0.02%, compared to VRNA's ROE of -0.39%. Regarding short-term risk, BNTX is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check VRNA's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, TECH has a market cap of 8.9B. Regarding current trading prices, BNTX is priced at $106.83, while TECH trades at $56.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas TECH's P/E ratio is 124.11. In terms of profitability, BNTX's ROE is -0.02%, compared to TECH's ROE of +0.06%. Regarding short-term risk, BNTX is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check TECH's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, BNTX is priced at $106.83, while IMGN trades at $31.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas IMGN's P/E ratio is -111.55. In terms of profitability, BNTX's ROE is -0.02%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, BNTX is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check IMGN's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, HALO has a market cap of 8.4B. Regarding current trading prices, BNTX is priced at $106.83, while HALO trades at $72.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas HALO's P/E ratio is 16.43. In terms of profitability, BNTX's ROE is -0.02%, compared to HALO's ROE of +1.37%. Regarding short-term risk, BNTX is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check HALO's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, BNTX is priced at $106.83, while BPMC trades at $129.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas BPMC's P/E ratio is -51.58. In terms of profitability, BNTX's ROE is -0.02%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, BNTX is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check BPMC's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, BNTX is priced at $106.83, while CERE trades at $44.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas CERE's P/E ratio is -16.47. In terms of profitability, BNTX's ROE is -0.02%, compared to CERE's ROE of -0.72%. Regarding short-term risk, BNTX is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check CERE's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, ROIV has a market cap of 8.1B. Regarding current trading prices, BNTX is priced at $106.83, while ROIV trades at $11.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas ROIV's P/E ratio is -10.94. In terms of profitability, BNTX's ROE is -0.02%, compared to ROIV's ROE of -0.10%. Regarding short-term risk, BNTX is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check ROIV's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, BNTX is priced at $106.83, while ROIVW trades at $2.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, BNTX's ROE is -0.02%, compared to ROIVW's ROE of -0.10%. Regarding short-term risk, BNTX is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for BNTX.Check ROIVW's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, JAZZ has a market cap of 7.5B. Regarding current trading prices, BNTX is priced at $106.83, while JAZZ trades at $123.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas JAZZ's P/E ratio is -17.64. In terms of profitability, BNTX's ROE is -0.02%, compared to JAZZ's ROE of -0.10%. Regarding short-term risk, BNTX is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check JAZZ's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, CORT has a market cap of 7.4B. Regarding current trading prices, BNTX is priced at $106.83, while CORT trades at $69.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas CORT's P/E ratio is 62.79. In terms of profitability, BNTX's ROE is -0.02%, compared to CORT's ROE of +0.20%. Regarding short-term risk, BNTX is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check CORT's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, RVMD has a market cap of 6.9B. Regarding current trading prices, BNTX is priced at $106.83, while RVMD trades at $36.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas RVMD's P/E ratio is -8.19. In terms of profitability, BNTX's ROE is -0.02%, compared to RVMD's ROE of -0.42%. Regarding short-term risk, BNTX is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check RVMD's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, RYTM has a market cap of 6.9B. Regarding current trading prices, BNTX is priced at $106.83, while RYTM trades at $100.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas RYTM's P/E ratio is -34.31. In terms of profitability, BNTX's ROE is -0.02%, compared to RYTM's ROE of -1.55%. Regarding short-term risk, BNTX is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check RYTM's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, IONS has a market cap of 6.8B. Regarding current trading prices, BNTX is priced at $106.83, while IONS trades at $42.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas IONS's P/E ratio is -24.26. In terms of profitability, BNTX's ROE is -0.02%, compared to IONS's ROE of -0.45%. Regarding short-term risk, BNTX is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check IONS's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, BNTX is priced at $106.83, while RETA trades at $172.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas RETA's P/E ratio is -66.29. In terms of profitability, BNTX's ROE is -0.02%, compared to RETA's ROE of +0.47%. Regarding short-term risk, BNTX is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check RETA's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, RNA has a market cap of 6B. Regarding current trading prices, BNTX is priced at $106.83, while RNA trades at $45.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas RNA's P/E ratio is -13.02. In terms of profitability, BNTX's ROE is -0.02%, compared to RNA's ROE of -0.33%. Regarding short-term risk, BNTX is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check RNA's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, AXSM has a market cap of 5.9B. Regarding current trading prices, BNTX is priced at $106.83, while AXSM trades at $116.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas AXSM's P/E ratio is -23.37. In terms of profitability, BNTX's ROE is -0.02%, compared to AXSM's ROE of -3.58%. Regarding short-term risk, BNTX is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check AXSM's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, ABVX has a market cap of 5.8B. Regarding current trading prices, BNTX is priced at $106.83, while ABVX trades at $76.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas ABVX's P/E ratio is -22.53. In terms of profitability, BNTX's ROE is -0.02%, compared to ABVX's ROE of -1.62%. Regarding short-term risk, BNTX is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check ABVX's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, BNTX is priced at $106.83, while ABCM trades at $23.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, BNTX's ROE is -0.02%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, BNTX is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check ABCM's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, BNTX is priced at $106.83, while ISEE trades at $39.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas ISEE's P/E ratio is -22.44. In terms of profitability, BNTX's ROE is -0.02%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, BNTX is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check ISEE's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, NUVL has a market cap of 5.5B. Regarding current trading prices, BNTX is priced at $106.83, while NUVL trades at $74.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas NUVL's P/E ratio is -15.46. In terms of profitability, BNTX's ROE is -0.02%, compared to NUVL's ROE of -0.33%. Regarding short-term risk, BNTX is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check NUVL's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, MRUS has a market cap of 5.1B. Regarding current trading prices, BNTX is priced at $106.83, while MRUS trades at $67.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas MRUS's P/E ratio is -12.09. In terms of profitability, BNTX's ROE is -0.02%, compared to MRUS's ROE of -0.55%. Regarding short-term risk, BNTX is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check MRUS's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, CRSP has a market cap of 4.9B. Regarding current trading prices, BNTX is priced at $106.83, while CRSP trades at $54.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas CRSP's P/E ratio is -10.06. In terms of profitability, BNTX's ROE is -0.02%, compared to CRSP's ROE of -0.25%. Regarding short-term risk, BNTX is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check CRSP's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, ALKS has a market cap of 4.9B. Regarding current trading prices, BNTX is priced at $106.83, while ALKS trades at $29.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas ALKS's P/E ratio is 14.37. In terms of profitability, BNTX's ROE is -0.02%, compared to ALKS's ROE of +0.24%. Regarding short-term risk, BNTX is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check ALKS's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, TGTX has a market cap of 4.7B. Regarding current trading prices, BNTX is priced at $106.83, while TGTX trades at $29.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas TGTX's P/E ratio is 77.49. In terms of profitability, BNTX's ROE is -0.02%, compared to TGTX's ROE of +0.29%. Regarding short-term risk, BNTX is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check TGTX's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, CYTK has a market cap of 4.6B. Regarding current trading prices, BNTX is priced at $106.83, while CYTK trades at $38.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas CYTK's P/E ratio is -7.49. In terms of profitability, BNTX's ROE is -0.02%, compared to CYTK's ROE of +3.09%. Regarding short-term risk, BNTX is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check CYTK's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, BNTX is priced at $106.83, while ALPN trades at $64.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas ALPN's P/E ratio is -101.52. In terms of profitability, BNTX's ROE is -0.02%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, BNTX is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check ALPN's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, AAPG has a market cap of 4.4B. Regarding current trading prices, BNTX is priced at $106.83, while AAPG trades at $44.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas AAPG's P/E ratio is -64.62. In terms of profitability, BNTX's ROE is -0.02%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, BNTX is less volatile compared to AAPG. This indicates potentially lower risk in terms of short-term price fluctuations for BNTX.Check AAPG's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, KRYS has a market cap of 4.4B. Regarding current trading prices, BNTX is priced at $106.83, while KRYS trades at $148.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas KRYS's P/E ratio is 30.59. In terms of profitability, BNTX's ROE is -0.02%, compared to KRYS's ROE of +0.15%. Regarding short-term risk, BNTX is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check KRYS's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, ACAD has a market cap of 4.3B. Regarding current trading prices, BNTX is priced at $106.83, while ACAD trades at $25.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas ACAD's P/E ratio is 19.35. In terms of profitability, BNTX's ROE is -0.02%, compared to ACAD's ROE of +0.31%. Regarding short-term risk, BNTX is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check ACAD's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, ADMA has a market cap of 4.2B. Regarding current trading prices, BNTX is priced at $106.83, while ADMA trades at $17.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas ADMA's P/E ratio is 20.94. In terms of profitability, BNTX's ROE is -0.02%, compared to ADMA's ROE of +0.62%. Regarding short-term risk, BNTX is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check ADMA's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, TLX has a market cap of 4.2B. Regarding current trading prices, BNTX is priced at $106.83, while TLX trades at $12.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas TLX's P/E ratio is 624.00. In terms of profitability, BNTX's ROE is -0.02%, compared to TLX's ROE of +0.10%. Regarding short-term risk, BNTX is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check TLX's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, BNTX is priced at $106.83, while OPT trades at $3.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas OPT's P/E ratio is -1.52. In terms of profitability, BNTX's ROE is -0.02%, compared to OPT's ROE of +2.60%. Regarding short-term risk, BNTX is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check OPT's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, PCVX has a market cap of 4.2B. Regarding current trading prices, BNTX is priced at $106.83, while PCVX trades at $30.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas PCVX's P/E ratio is -7.86. In terms of profitability, BNTX's ROE is -0.02%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, BNTX is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for BNTX.Check PCVX's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, BNTX is priced at $106.83, while MRTX trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas MRTX's P/E ratio is -4.82. In terms of profitability, BNTX's ROE is -0.02%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, BNTX is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check MRTX's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, PTCT has a market cap of 4B. Regarding current trading prices, BNTX is priced at $106.83, while PTCT trades at $49.68.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas PTCT's P/E ratio is 7.17. In terms of profitability, BNTX's ROE is -0.02%, compared to PTCT's ROE of -0.99%. Regarding short-term risk, BNTX is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check PTCT's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, ACLX has a market cap of 4B. Regarding current trading prices, BNTX is priced at $106.83, while ACLX trades at $68.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas ACLX's P/E ratio is -20.90. In terms of profitability, BNTX's ROE is -0.02%, compared to ACLX's ROE of -0.43%. Regarding short-term risk, BNTX is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check ACLX's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, AKRO has a market cap of 3.9B. Regarding current trading prices, BNTX is priced at $106.83, while AKRO trades at $48.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas AKRO's P/E ratio is -12.92. In terms of profitability, BNTX's ROE is -0.02%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, BNTX is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check AKRO's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, ZLAB has a market cap of 3.9B. Regarding current trading prices, BNTX is priced at $106.83, while ZLAB trades at $34.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas ZLAB's P/E ratio is -17.52. In terms of profitability, BNTX's ROE is -0.02%, compared to ZLAB's ROE of -0.27%. Regarding short-term risk, BNTX is more volatile compared to ZLAB. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check ZLAB's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, BNTX is priced at $106.83, while RYZB trades at $62.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas RYZB's P/E ratio is -57.86. In terms of profitability, BNTX's ROE is -0.02%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, BNTX is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check RYZB's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, BNTX is priced at $106.83, while CBAY trades at $32.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas CBAY's P/E ratio is -32.81. In terms of profitability, BNTX's ROE is -0.02%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, BNTX is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check CBAY's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, SLNO has a market cap of 3.6B. Regarding current trading prices, BNTX is priced at $106.83, while SLNO trades at $66.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas SLNO's P/E ratio is -16.25. In terms of profitability, BNTX's ROE is -0.02%, compared to SLNO's ROE of -0.74%. Regarding short-term risk, BNTX is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check SLNO's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, MIRM has a market cap of 3.6B. Regarding current trading prices, BNTX is priced at $106.83, while MIRM trades at $71.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas MIRM's P/E ratio is -59.11. In terms of profitability, BNTX's ROE is -0.02%, compared to MIRM's ROE of -0.25%. Regarding short-term risk, BNTX is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check MIRM's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, PTGX has a market cap of 3.6B. Regarding current trading prices, BNTX is priced at $106.83, while PTGX trades at $57.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas PTGX's P/E ratio is 78.74. In terms of profitability, BNTX's ROE is -0.02%, compared to PTGX's ROE of +0.08%. Regarding short-term risk, BNTX is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check PTGX's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, MLTX has a market cap of 3.5B. Regarding current trading prices, BNTX is priced at $106.83, while MLTX trades at $55.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas MLTX's P/E ratio is -20.03. In terms of profitability, BNTX's ROE is -0.02%, compared to MLTX's ROE of -0.42%. Regarding short-term risk, BNTX is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check MLTX's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, BNTX is priced at $106.83, while SWTX trades at $46.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas SWTX's P/E ratio is -13.78. In terms of profitability, BNTX's ROE is -0.02%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, BNTX is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check SWTX's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, APLS has a market cap of 3.5B. Regarding current trading prices, BNTX is priced at $106.83, while APLS trades at $27.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas APLS's P/E ratio is -15.28. In terms of profitability, BNTX's ROE is -0.02%, compared to APLS's ROE of -1.16%. Regarding short-term risk, BNTX is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check APLS's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, MTSR has a market cap of 3.5B. Regarding current trading prices, BNTX is priced at $106.83, while MTSR trades at $32.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas MTSR's P/E ratio is -11.24. In terms of profitability, BNTX's ROE is -0.02%, compared to MTSR's ROE of -0.90%. Regarding short-term risk, BNTX is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for BNTX.Check MTSR's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, SRRK has a market cap of 3.4B. Regarding current trading prices, BNTX is priced at $106.83, while SRRK trades at $34.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas SRRK's P/E ratio is -12.15. In terms of profitability, BNTX's ROE is -0.02%, compared to SRRK's ROE of -1.27%. Regarding short-term risk, BNTX is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check SRRK's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, LEGN has a market cap of 3.3B. Regarding current trading prices, BNTX is priced at $106.83, while LEGN trades at $35.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas LEGN's P/E ratio is -19.98. In terms of profitability, BNTX's ROE is -0.02%, compared to LEGN's ROE of -0.31%. Regarding short-term risk, BNTX is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check LEGN's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, KYMR has a market cap of 3.2B. Regarding current trading prices, BNTX is priced at $106.83, while KYMR trades at $43.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas KYMR's P/E ratio is -12.64. In terms of profitability, BNTX's ROE is -0.02%, compared to KYMR's ROE of -0.32%. Regarding short-term risk, BNTX is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check KYMR's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, LGND has a market cap of 3.1B. Regarding current trading prices, BNTX is priced at $106.83, while LGND trades at $158.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas LGND's P/E ratio is -39.38. In terms of profitability, BNTX's ROE is -0.02%, compared to LGND's ROE of -0.09%. Regarding short-term risk, BNTX is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check LGND's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, XENE has a market cap of 3B. Regarding current trading prices, BNTX is priced at $106.83, while XENE trades at $38.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas XENE's P/E ratio is -10.94. In terms of profitability, BNTX's ROE is -0.02%, compared to XENE's ROE of -0.39%. Regarding short-term risk, BNTX is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check XENE's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, ARWR has a market cap of 2.9B. Regarding current trading prices, BNTX is priced at $106.83, while ARWR trades at $20.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas ARWR's P/E ratio is -17.76. In terms of profitability, BNTX's ROE is -0.02%, compared to ARWR's ROE of -0.41%. Regarding short-term risk, BNTX is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check ARWR's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, VKTX has a market cap of 2.9B. Regarding current trading prices, BNTX is priced at $106.83, while VKTX trades at $25.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas VKTX's P/E ratio is -16.88. In terms of profitability, BNTX's ROE is -0.02%, compared to VKTX's ROE of -0.20%. Regarding short-term risk, BNTX is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for BNTX.Check VKTX's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, CRNX has a market cap of 2.9B. Regarding current trading prices, BNTX is priced at $106.83, while CRNX trades at $30.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas CRNX's P/E ratio is -7.54. In terms of profitability, BNTX's ROE is -0.02%, compared to CRNX's ROE of -0.32%. Regarding short-term risk, BNTX is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check CRNX's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, RARE has a market cap of 2.9B. Regarding current trading prices, BNTX is priced at $106.83, while RARE trades at $29.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas RARE's P/E ratio is -5.43. In terms of profitability, BNTX's ROE is -0.02%, compared to RARE's ROE of -2.37%. Regarding short-term risk, BNTX is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check RARE's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, BNTX is priced at $106.83, while MORF trades at $56.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas MORF's P/E ratio is -14.88. In terms of profitability, BNTX's ROE is -0.02%, compared to MORF's ROE of -0.16%. Regarding short-term risk, BNTX is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check MORF's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, BNTX is priced at $106.83, while MOR trades at $18.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas MOR's P/E ratio is -12.64. In terms of profitability, BNTX's ROE is -0.02%, compared to MOR's ROE of -1.84%. Regarding short-term risk, BNTX is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check MOR's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, NAMS has a market cap of 2.8B. Regarding current trading prices, BNTX is priced at $106.83, while NAMS trades at $24.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas NAMS's P/E ratio is -15.72. In terms of profitability, BNTX's ROE is -0.02%, compared to NAMS's ROE of -0.25%. Regarding short-term risk, BNTX is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check NAMS's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, BNTX is priced at $106.83, while KDNY trades at $40.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas KDNY's P/E ratio is -12.47. In terms of profitability, BNTX's ROE is -0.02%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, BNTX is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check KDNY's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, IMVT has a market cap of 2.7B. Regarding current trading prices, BNTX is priced at $106.83, while IMVT trades at $14.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas IMVT's P/E ratio is -5.37. In terms of profitability, BNTX's ROE is -0.02%, compared to IMVT's ROE of -0.84%. Regarding short-term risk, BNTX is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check IMVT's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, BNTX is priced at $106.83, while MYOV trades at $26.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas MYOV's P/E ratio is -14.05. In terms of profitability, BNTX's ROE is -0.02%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, BNTX is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check MYOV's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, CPRX has a market cap of 2.6B. Regarding current trading prices, BNTX is priced at $106.83, while CPRX trades at $21.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas CPRX's P/E ratio is 12.78. In terms of profitability, BNTX's ROE is -0.02%, compared to CPRX's ROE of +0.27%. Regarding short-term risk, BNTX is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check CPRX's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, KNSA has a market cap of 2.5B. Regarding current trading prices, BNTX is priced at $106.83, while KNSA trades at $33.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas KNSA's P/E ratio is 675.00. In terms of profitability, BNTX's ROE is -0.02%, compared to KNSA's ROE of +0.01%. Regarding short-term risk, BNTX is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check KNSA's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, VCYT has a market cap of 2.4B. Regarding current trading prices, BNTX is priced at $106.83, while VCYT trades at $29.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas VCYT's P/E ratio is 91.18. In terms of profitability, BNTX's ROE is -0.02%, compared to VCYT's ROE of +0.02%. Regarding short-term risk, BNTX is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check VCYT's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, TARS has a market cap of 2.4B. Regarding current trading prices, BNTX is priced at $106.83, while TARS trades at $56.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas TARS's P/E ratio is -25.00. In terms of profitability, BNTX's ROE is -0.02%, compared to TARS's ROE of -0.32%. Regarding short-term risk, BNTX is more volatile compared to TARS. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check TARS's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, BNTX is priced at $106.83, while PRVB trades at $24.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas PRVB's P/E ratio is -16.43. In terms of profitability, BNTX's ROE is -0.02%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, BNTX is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check PRVB's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, FOLD has a market cap of 2.3B. Regarding current trading prices, BNTX is priced at $106.83, while FOLD trades at $7.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas FOLD's P/E ratio is -63.42. In terms of profitability, BNTX's ROE is -0.02%, compared to FOLD's ROE of -0.20%. Regarding short-term risk, BNTX is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check FOLD's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, BNTX is priced at $106.83, while LBPH trades at $59.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas LBPH's P/E ratio is -26.66. In terms of profitability, BNTX's ROE is -0.02%, compared to LBPH's ROE of -0.21%. Regarding short-term risk, BNTX is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check LBPH's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, LQDA has a market cap of 2.3B. Regarding current trading prices, BNTX is priced at $106.83, while LQDA trades at $26.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas LQDA's P/E ratio is -14.75. In terms of profitability, BNTX's ROE is -0.02%, compared to LQDA's ROE of -1.58%. Regarding short-term risk, BNTX is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check LQDA's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, APGE has a market cap of 2.3B. Regarding current trading prices, BNTX is priced at $106.83, while APGE trades at $37.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas APGE's P/E ratio is -9.24. In terms of profitability, BNTX's ROE is -0.02%, compared to APGE's ROE of -0.23%. Regarding short-term risk, BNTX is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check APGE's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, CNTA has a market cap of 2.3B. Regarding current trading prices, BNTX is priced at $106.83, while CNTA trades at $17.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas CNTA's P/E ratio is -9.19. In terms of profitability, BNTX's ROE is -0.02%, compared to CNTA's ROE of -0.56%. Regarding short-term risk, BNTX is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check CNTA's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, BNTX is priced at $106.83, while DICE trades at $47.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas DICE's P/E ratio is -21.91. In terms of profitability, BNTX's ROE is -0.02%, compared to DICE's ROE of +0.56%. Regarding short-term risk, BNTX is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check DICE's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, DNLI has a market cap of 2.3B. Regarding current trading prices, BNTX is priced at $106.83, while DNLI trades at $15.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas DNLI's P/E ratio is -5.51. In terms of profitability, BNTX's ROE is -0.02%, compared to DNLI's ROE of -0.41%. Regarding short-term risk, BNTX is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check DNLI's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, AGIO has a market cap of 2.3B. Regarding current trading prices, BNTX is priced at $106.83, while AGIO trades at $38.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas AGIO's P/E ratio is 3.44. In terms of profitability, BNTX's ROE is -0.02%, compared to AGIO's ROE of +0.43%. Regarding short-term risk, BNTX is more volatile compared to AGIO. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check AGIO's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, CELC has a market cap of 2.2B. Regarding current trading prices, BNTX is priced at $106.83, while CELC trades at $51.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas CELC's P/E ratio is -15.11. In terms of profitability, BNTX's ROE is -0.02%, compared to CELC's ROE of -1.50%. Regarding short-term risk, BNTX is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check CELC's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, IDYA has a market cap of 2.2B. Regarding current trading prices, BNTX is priced at $106.83, while IDYA trades at $24.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas IDYA's P/E ratio is -6.54. In terms of profitability, BNTX's ROE is -0.02%, compared to IDYA's ROE of -0.31%. Regarding short-term risk, BNTX is more volatile compared to IDYA. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check IDYA's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, IBRX has a market cap of 2.2B. Regarding current trading prices, BNTX is priced at $106.83, while IBRX trades at $2.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas IBRX's P/E ratio is -4.81. In terms of profitability, BNTX's ROE is -0.02%, compared to IBRX's ROE of +0.61%. Regarding short-term risk, BNTX is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check IBRX's competition here

BNTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BNTX stands at 26.7B. In comparison, HRMY has a market cap of 2.2B. Regarding current trading prices, BNTX is priced at $106.83, while HRMY trades at $37.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BNTX currently has a P/E ratio of -66.80, whereas HRMY's P/E ratio is 12.21. In terms of profitability, BNTX's ROE is -0.02%, compared to HRMY's ROE of +0.26%. Regarding short-term risk, BNTX is more volatile compared to HRMY. This indicates potentially higher risk in terms of short-term price fluctuations for BNTX.Check HRMY's competition here